Pfizer Feels The Heat As ThermaCare Recall Spreads To Europe
Executive Summary
A problem with overheating heat cells in Pfizer's ThermaCare OTC pain-relief patch is not limited to the US market, the company has discovered, prompting recalls across four European markets.
You may also be interested in...
US Startup Ignites Consumer Health Portfolio Build With North American Rights To ThermaCare
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.
GSK And Pfizer Agree To Divest ThermaCare To Win EU Approval For JV
GSK and Pfizer must find a buyer for the global rights to the ThermaCare pain relief brand to receive European Commission approval for their proposed joint venture.
Leaking Heat Cells In Pfizer's ThermaCare HeatWraps Prompt Recall
Firm's consumer health division extends to consumer level a recall it advised retailers and distributors about on Oct. 2 because products from the six lots have a potential to leak ingredients contained in heat cell wraps. A leaking heat cell in a HeatWrap could cause skin injuries such as burns, blisters or skin irritation on the applied areas.